Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation |
|---|
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
In recent months, a new coronavirus, SARS-CoV-2, has been identified as the cause of a serious lung infection named COVID-19 by the World Health Organization. This virus has spread rapidly among the nations of the world and it is the cause of a pandemic and a global health emergency. There is still very little scientific evidence on the virus, however epidemiological data suggest that one of the most frequent comorbidities is diabetes, along with hypertension and heart disease. There is no scientific evidence on the possible effects of this infection on the function of the β cell and on glycemic control. Clinical evidence seems to suggest that COVID-19 infection mostly affects the respiratory system, and an acute worsening of glycemic compensation is not described as generally observed in bacterial pneumonia. However, previous work on acute respiratory syndromes (SARS) caused by similar coronaviruses, had described that the infection has multi-organ involvement related to the expression of the SARS coronavirus receptor, the angiotensin 2 converting enzyme, in different organs, especially at the level of endocrine pancreatic tissue. In the population of this previous work, glucose intolerance and fasting hyperglycaemia have been described and in 37 of 39 diabetic patients examined, a remission of diabetes was observed three years after the infection. It is possible that the coronaviruses responsible for SARS may enter the pancreatic islets using the angiotensin 2 converting enzyme receptor, expressed at the level of the endocrine pancreas, thus causing diabetes. Additionally, previous literature on coronavirus infections (SARS and MERS or Middle-East Respiratory Syndrome) suggested that diabetes could worsen the evolution of the disease. In particular, in case of Middle-East Respiratory Syndrome-CoV infection, diabetic mice had a more prolonged serious illness and a delay in recovery regardless of the viremic titer. This could probably be due to a dysregulation of the immune response, which results in more serious and prolonged lung disease. There are currently no data on pancreatic beta cell function in patients with COVID-19.
Description: Difference in insulin levels during and after COVID-19 infection and compared to patients in the control group
Measure: Serum β - cellular function index insulin levels Time: 12 monthsDescription: Difference in C-peptide levels during and after COVID-19 infection and compared to patients in the control group
Measure: Serum β - cellular function index C-peptide levels Time: 12 monthsDescription: Difference in HOMA-β index during and after COVID-19 infection and compared to patients in the control group
Measure: Serum β - cellular function HOMA-β index Time: 12 monthsDescription: Difference in pro-insulin/insulin ratio during and after COVID-19 infection and compared to patients in the control group
Measure: Serum β - cellular function pro-insulin/insulin ratio Time: 12 monthsDescription: Check for the existence of damage to the beta cell function induced by COVID-19 infection, clinically observable with changes in the secretory response of insulin
Measure: Evaluation of the secretory response of insulin to the arginine stimulation test Time: 12 monthsDescription: Presence of SARS-CoV-2 viral particles in β cells in COVID-19 patient samples
Measure: Viral SARS-CoV-2 particles in β cells Time: 12 monthsDescription: Evidence of impairment of β cell function in the serum of COVID-19 patients
Measure: Percentage of patients with preserved β cells function Time: 12 monthsDescription: Changes in glucose values in COVID-19 patients and healthy volunteers
Measure: Glucose values Time: 12 monthsDescription: Changes in the values of continuous glucose monitoring in both COVID-19 patients and healthy volunteers
Measure: Values of continuous glucose monitoring Time: 12 monthsDescription: Comparison of interleukin 1-β levels in COVID-19 patients compared with healthy subjects
Measure: Changes in the inflammatory marker interleukin 1-β Time: 12 monthsDescription: Comparison of interleukin IL-2 levels in COVID-19 patients compared with healthy subjects
Measure: Changes in the inflammatory marker interleukin IL-2 Time: 12 monthsDescription: Comparison of interleukin IL-6 levels in COVID-19 patients compared with healthy subjects
Measure: Changes in the inflammatory marker interleukin IL-6 Time: 12 monthsDescription: Comparison of interleukin IL-7 levels in COVID-19 patients compared with healthy subjects
Measure: Changes in the inflammatory marker interleukin IL-7 Time: 12 monthsDescription: Comparison of interleukin IL-10 levels in COVID-19 patients compared with healthy subjects
Measure: Changes in the inflammatory marker interleukin IL-10 Time: 12 monthsDescription: Comparison of interleukin tumor necrosis factor-α levels in COVID-19 patients compared with healthy subjects
Measure: Changes in the inflammatory marker tumor necrosis factor-α Time: 12 monthsDescription: Comparison of interferon gamma levels in COVID-19 patients compared with healthy subjects
Measure: Changes in the inflammatory marker interferon gamma Time: 12 monthsDescription: Comparison of macrophage inflammatory protein-1β levels in COVID-19 patients compared with healthy subjects
Measure: Changes in the inflammatory marker macrophage inflammatory protein-1β Time: 12 monthsDescription: Comparison of macrophage inflammatory monocyte chemoattractant protein-1 in COVID-19 patients compared with healthy subjects
Measure: Changes in the inflammatory marker monocyte chemoattractant protein-1 Time: 12 monthsDescription: Comparison of macrophage inflammatory granulocyte-macrophage colony-stimulating factor in COVID-19 patients compared with healthy subjects
Measure: Changes in the inflammatory marker granulocyte-macrophage colony-stimulating factor Time: 12 monthsDescription: Comparison of macrophage inflammatory granulocyte colony-stimulating factor in COVID-19 patients compared with healthy subjects
Measure: Changes in the inflammatory marker granulocyte colony-stimulating factor Time: 12 monthsAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports